Navigation Links
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Date:6/25/2008

SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the company has successfully completed first-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine manufacturing process with the potential to produce several million doses of vaccines in a matter of days.

The RapidResponse(TM) system is designed to allow extremely rapid and large-scale production of DNA vaccines with low capital requirements. It is ideally suited to enable an immediate response against emerging diseases affecting large populations, such as pandemic influenza or severe acute respiratory syndrome (SARS). The company is proceeding with the development of the RapidResponse(TM) platform under the second year of grant funding awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Separately, Vical has completed enrollment in its Phase 1 testing of the company's Vaxfectin(R)-formulated pandemic influenza DNA vaccines, and expects to release results by August 2008.

About the RapidResponse(TM) Platform

The RapidResponse(TM) DNA vaccine manufacturing platform is intended to significantly reduce the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak. By using a cell-free manufacturing process, the company believes that the RapidResponse(TM) DNA platform can overcome the time, capacity and cost challenges of manufacturing conventional vaccines for diseases such as influenza, which use viruses grown in chicken eggs or via cell culture, requiring months of production time in large, dedicated
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)..., Nov. 25 Poniard,Pharm...tical company focused on,innovative oncology ther...strategic alternatives for its preclinical researc... its resources on the clinical development of pico...t the initial commercialization of,picoplatin in ...
(Date:11/25/2008)...ire-FirstCall/ -- CardioVascular,BioTherapeutics,...that it has,dosed the first patient in North Amer...rial to treat patients with severe coronary heart ...t of CORonary heart Disease) trial will include,f...oses in approximately 120,patients with severe co...
(Date:11/24/2008)...PRNewswire-FirstCall/ -- Leaders of Schering-Ploug...ate for investors on the company,s research pipeli...hat includes 46 new entities in clinical trials or...dies. , , "Research and development is addi...ontinue our transformation," said Fred Hassan, cha...
(Date:11/24/2008)...day Unveils Rich Development Pipeline of Compounds...ORTH, N.J., Nov. 24 Sche...led top-line results of a long-term Phase III clin...S(TM) (asenapine) demonstrating efficacy and safet... trial, asenapine was statistically significantly ...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3Hear Indiana Announces Talk Walk Run 2008 18272 1Hear Indiana Announces Talk Walk Run 2008 18272 2Hear Indiana Announces Talk Walk Run 2008 18272 3Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 1Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 1Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 3GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 1GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 2GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 3
... /PRNewswire/ -- Results of the,Option (TOcilizuma...ers) trial, the first multinational Phase III stud...ith Actemra (either 4mg/kg,or 8mg/kg) plus methotr...ant improvement in the signs and symptoms of moder...o patients treated with,placebo and methotrexate, ...
...Biotech (OMX Nordic: ACTI) presented,pre-clinical ...The,European League Against Rheumatism, <a target=...rg ) conference, June,13-16*. , "The new pre-clin...nt inhibitory effect on disease development in an,... commented Sven,Andréasson, President &...
Other Medicine Technology:Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
(Date:12/2/2008)... Orion Health announces that the Sou...of Juneau, Alaska, has selected the Rhapsody&trade...nic health record, radiology, pharmacy, laboratory.... It also plans to extend connectivity to statewid...unization registry) and AKAIMS (an MIS and clinica...
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)...es ,Asthma & Allergy Friendly, Toy Puppies to ... Much has been made of P...ily dog. But concerns about his daughter,s asthma...ew first-dad from making a decision. So, in the m...ica (AAFA) is donating 2 "asthma & allergy fri...
(Date:12/1/2008)...New research reveals that computed tomography (CT)...has the potential to screen for two diseases at on...h commonly affect adults over age 50. Results of t...ting of the Radiological Society of North America ...screening for colorectal cancer, we were able to i...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...id could provide ample energy if used properly is ...rican Journal of Physiology - Endocrinology and Me...d colleagues Takeshi Hashimoto and Rajaa Hussien i...ratory add one of the last puzzle pieces to the la...
... to a report published in Geneva it was found that...research work on diseases such as AIDS and malaria... many developing countries, especially in sub-Saha...y the Global Forum for Health Research. Stephen Ma...
...cefully can sometimes be a problem especially when... facilities looms large. //Marilyn Rantz, nursing ... calls this as a slippery slope and says that ther...m getting onto this slope. Consumers say they nev...
...more number of bus drivers and conductors in India...is that of the bus conductor Ravindra Kamble (34).... conductors in the last one year have been tested ...programme was started by General Manager SS Kshatr...
Other Medicine News:Health News:Lactic acid a potent energy giver if used properly! 2
Inquiry H Steerable Catheter. Steerable atrial mapping catheter offers a variety of designs and a unique 45 offset for catheter stability. 10 to 24 electrodes, regular and large steerable curves, ina
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...or a complete line of deflectable coronary sinus (...all with the quality, reliability and precise perf...atheter technology. All of our deflectable coronar...gned and constructed to help minimize the frustrat...
Inquiry 5FR Soft HIS diagnostic catheters provide the electrophysiologist with a uniquely designed curve that allows for placement and recording in the HIS bundle. In addition, the soft tubing is des
Medicine Products: